Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Marshall Fordyce
|
| gptkbp:clinicalTrialPhase |
Phase 3 (atacicept for IgA nephropathy)
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusesOn |
immunological diseases
|
| gptkbp:foundedYear |
2016
|
| gptkbp:founder |
Marshall Fordyce
|
| gptkbp:headquartersLocation |
gptkb:Brisbane,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vera Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:products |
gptkb:atacicept
MAU868 |
| gptkbp:stockSymbol |
gptkb:VERA
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
https://www.veratx.com/
|
| gptkbp:bfsParent |
gptkb:Nano_Precision_Medical
|
| gptkbp:bfsLayer |
7
|